Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient

AVEO Pharmaceuticals

Status

Conditions

Mullerian Mixed Tumor of Ovary

Treatments

Drug: ficlatuzumab

Study type

Expanded Access

Funder types

Industry

Identifiers

NCT02090127

AV-299-13-103S

Details and patient eligibility

About

Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient

Full description

This treatment protocol will serve as a mechanism to continue to provide ficlatuzumab to patient 0001-000412, who was previously enrolled under protocol P05538 and whom the investigator believes is deriving clinical benefit from ficlatuzumab treatment.

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria